Expression of survivin and p53 proteins and their correlation with hormone receptor status in Indian breast cancer patients

Nerurkar, AV; Phulpagar, MD; Shirsat, NV; Ranade, KJ

doi:10.4103/0019-5359.58877

Cited by 12 publications

(10 citation statements)

References 20 publications

(22 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our group of 80 breast carcinomas, survivin was expressed in 67 cases (83.8%). These results are in agreement with the literature, since many other studies describe similar findings [14,16,18,19,26]. Taken together, survivin overexpression was noted mainly in human malignant tumors.…”

Section: Discussionsupporting

confidence: 93%

“…In contrast to carcinomas, rare studies were performed on survivin expression in benign breast tumors. Its expression was reported by Ranade et al [19] in 17 out of 32 fibroadenoma cases (53%), positivity was observed mainly in cytoplasm. In 4 out of 32 of these benign lesions (13%), a distinct nuclear immunoreactions along with cytoplasmic location was shown.…”

Section: Discussionmentioning

confidence: 52%

“…Our results are almost consistent with the observation of Ryan et al [23], who detected 67.7% survivin positivity in fibroadenomas (21 out of 31 cases). Survivin expression in benign cases is likely to result from the proliferation and /or dysplastic transformation of luminal epithelial cells [19]. It is known that survivin inhibits apoptosis and promotes cell proliferation and angiogenesis.…”

Section: Discussionmentioning

confidence: 99%

“…In research studies, there is no conformity with the interpretation of immunohistochemical survivin expression in breast tumor cells [14,16,17]. Furthermore, the review of literature revealed diametrically opposed results of survivin expression in normal mammary tissue [16,18,19]. In the present study, we report the expression pattern of protein in question with respect to relative number of positively stained cells, intensity of staining and subcellular location as detected by immunohistochemical methods in 13 cases of normal breast tissue, in a panel of 38 benign breast tumors and 80 breast carcinomas, respectively.…”

mentioning

confidence: 99%

See 3 more Smart Citations

Survivin: a promising biomarker in breast carcinoma

Adamkov

Halašová²,

Kajo³

et al. 2010

neo

View full text Add to dashboard Cite

The antiapoptotic protein survivin can be detected in most types of malignant tumors, but it is rarely expressed in corresponding normal adult tissues. Therefore, survivin appears to represent a promising diagnostic biomarker. We examined survivin expression in 13 cases of normal breast tissue, 38 cases of fibroadenomas and 80 cases of breast carcinomas by immunohistochemical staining using anti-survivin antibody (DAKO, Clone 12C4). In each section, the intensity of staining, percentage of labeled cells, and the subcellular location of survivin antigen were assessed. Survivin was detected in 4/13 cases of normal breast tissue (30.7%), in 28/38 cases of fibroadenomas (73.7%), and in 67/80 cases of carcinomas (83.8%). Normal breast tissue showed cytoplasmic positivity only. In fibroadenomas, 19 cases (50.0%) revealed cytoplasmic reaction, and in 9 cases (23.7%), small foci of cells with combined nuclear and cytoplasmic location were identified. In carcinomas, cytoplasmic staining was found in 12/80 cases (15.0%), nuclear staining in 10/80 cases (12.5%), and combined cytoplasmic and nuclear staining in 45/80 cases (56.3%). Subcellular location of survivin between benign and malignant lesions revealed significant differences (p<0,001). Our findings point at practical use of survivin detection. We confirm the importance of nuclear staining of survivin antigen in breast carcinoma, which seems to be a notable diagnostic marker for estimation of the degree of neoplasia.

show abstract

Section: Discussionsupporting

confidence: 93%

Section: Discussionmentioning

confidence: 52%

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

See 2 more Smart Citations

Survivin: a promising biomarker in breast carcinoma

Adamkov

Halašová²,

Kajo³

et al. 2010

neo

View full text Add to dashboard Cite

show abstract

“…In its normal form, p53 can be involved in the induction of apoptosis and thus has a regulatory function over the cell cycle. In its mutant form, p53 inhibits apoptosis, loses control on cell cycle progression and thus helps tumor formation [9]. Nuclear p53 accumulation which associates with p53 mutation is one of the most common events during breast carcinogenesis [10-12].…”

Section: Introductionmentioning

confidence: 99%

p53 nuclear accumulation and ERα expression in ductal hyperplasia of breast in a cohort of 215 Chinese women

Mao

Fan

Zheng

et al. 2010

J Exp Clin Cancer Res

View full text Add to dashboard Cite

IntroductionWomen with ductal hyperplasia including usual ductal hyperplasia (UDH) and atypical ductal hyperplasia (ADH) have an increased risk of developing invasive ductal carcinoma (IDC) of breast. The importance of several molecular markers in breast cancer has been of considerable interest during recent years such as p53 and estrogen receptor alpha (ERα). However, p53 nuclear accumulation and ERα expression have not been assessed in ductal hyperplasia co-existing with ductal carcinoma in situ (DCIS) or IDC versus pure ductal hyperplasia without DCIS or IDC.Materials and methodsWe investigated p53 nuclear accumulation and ERα expression in breast ductal hyperplasia in a cohort of 215 Chinese women by immunohistochemistry (IHC), which included 129 cases of pure ductal hyperplasia, 86 cases of ductal hyperplasia co-existing with DCIS (41 cases) or IDC (45 cases).ResultsNuclear p53 accumulation was identified in 22.8% of ADH (31/136), 41.5% of DCIS (17/41) and 42.2% of IDC (19/45), and no case of UDH (0/79). No difference in nuclear p53 accumulation was observed between pure ADH and ADH co-existing with DCIS (ADH/DCIS) or IDC (ADH/IDC) (P > 0.05). The positive rate of ERα expression was lower in ADH (118/136, 86.8%) than that in UDH (79/79, 100%) (P < 0.001), but higher than that in DCIS (28/41, 68.3%) or IDC (26/45, 57.8%) respectively (P < 0.001). The frequency of ERα expression was lower in ADH/DCIS (23/29, 79.31%) and ADH/IDC (23/30, 76.67%) than that in pure ADH (72/77, 93.51%) respectively (P < 0.05). There was a negative weak correlation between p53 nuclear accumulation and ERα expression as for ADH (coefficient correlation -0.51; P < 0.001).ConclusionsDifferent pathological types of ductal hyperplasia of breast are accompanied by diversity in patterns of nuclear p53 accumulation and ERα expression. At least some pure ADH is molecularly distinct from ADH/CIS or ADH/IDC which indicated the two types of ADH are molecularly distinct entities although they have the same morphological appearance.

show abstract